VANCOUVER, BRITISH COLUMBIA--(Marketwire - February 01, 2010) - Pyng Medical Corp. (TSX VENTURE: PYT) (the "Company" or "Pyng") announced today that it has opened its US sales office in Kirkland, Washington to service the growing demand for Pyng's line of resuscitative care solutions in the United States. The Kirkland office expands the Company's ability to offer sales and support services to its fast growing base of American customers, distribution partners and prospects.
Pyng is the first company to offer an adult intraosseous infusion device, and continues to lead in resuscitation innovation with simple-to-use, and highly-effective products including FAST1® Intraosseous Infusion System, FASTx™ Intraosseous Infusion Device, T-POD® Pelvic Stabilizer, and MAT® Tourniquet.
"We have seen significant growth in our customer base and level of interest in our resuscitation products and solutions," said Robert Di Silvio, President and CEO of the Pyng." Our customers are expanding their commitment to our life-saving devices, and with that commitment, to support their efforts, we are expanding our local resources. The Kirkland office will allow us to deliver superior sales and support to our US customers and to the growing prospect base."
The new office is located at:
Pyng Medical USA 5400 Carillon Point Building 5000 4th Floor Kirkland, Washington 98033 United States Main tel: 425 576 4000 Main fax: 877 439 2707About Pyng Medical Corp.
Pyng is the developer and manufacturer of the proprietary, award-winning FAST1™ Intraosseous Infusion System. Pyng was selected in the "2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1™ has worldwide application for use with hospitals, emergency medical services and military forces.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
